TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18681336

Group type: EXPERIMENTAL
Intervention: Prevention bonus program (intervention group)
Number of subjects: 70429

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70429
Study: 16178494

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin/β-lactam combination
Number of subjects: 8
Study: 12914864

Group type: EXPERIMENTAL
Intervention: Treadmill exercise echocardiography (EE)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Baseline echocardiography and ECG treadmill exercise testing
Number of subjects: 164
Study: 10577438

Group type: EXPERIMENTAL
Intervention: Niacin treatment (100 mg to 1000 mg daily)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Niacin treatment
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 8696422

Group type: EXPERIMENTAL
Intervention: High-MCT diet (HMCT)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Medium-MCT diet (MMCT)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Low-MCT diet (LMCT)
Number of subjects: 6
Study: 1752603

Group type: EXPERIMENTAL
Intervention: CC-hMG combination cycle
Number of subjects: 0

Group type: COMPARATOR
Intervention: hMG cycle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CC-hMG cycle
Number of subjects: 0
Study: 7040192

Group type: EXPERIMENTAL
Intervention: Progestogen only (Lynestrenol 0.5 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Combined oral contraceptive (ethinyl estradiol 50 micrograms + lynestrenol 2.5 micrograms)
Number of subjects: 23
Study: 31858136

Group type: EXPERIMENTAL
Intervention: Shorter treatment duration (5-9 days)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Longer treatment duration (10-15 days)
Number of subjects: 408
Study: 30967869

Group type: EXPERIMENTAL
Intervention: MBL2 rs1800450- AA genotype
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: High clinical risk score (≥1%) combined with MBL2 rs1800450-AA
Number of subjects: 1007

Group type: COMPARATOR
Intervention: Healthy controls (carrying rs1800450-AA)
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: IgAN patients (carrying rs1800450-AA)
Number of subjects: 1007
Study: 30261877

Group type: EXPERIMENTAL
Intervention: Intermittent Screening and Treatment (ISTp)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Intermittent Preventive Treatment (IPTp)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Single Screen and Treat (SSTp)
Number of subjects: 227
Study: 27381286

Group type: EXPERIMENTAL
Intervention: Dose reduction regimen of etanercept (50 mg/week for 4 weeks followed by 25 mg/week for 8 weeks)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional dose of etanercept (50 mg/week for 12 weeks)
Number of subjects: 43
Study: 25443043

Group type: EXPERIMENTAL
Intervention: Professional development (five days) and group-based consultation (14 sessions) for early childhood teachers
Number of subjects: 100

Group type: COMPARATOR
Intervention: Waitlist control group (no intervention)
Number of subjects: 100
Study: 23201982

Group type: EXPERIMENTAL
Intervention: Electronic nose analysis of stool samples before and four weeks after radiotherapy
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: FAIMS analysis of stool samples before and four weeks after radiotherapy
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Pre-treatment stool samples analysis
Number of subjects: 23
Study: 18249383

Group type: EXPERIMENTAL
Intervention: Hormone Therapy (HT)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 120
Study: 17577027

Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate every-3-months depot (LAD-3M)
Number of subjects: 599

Group type: COMPARATOR
Intervention: Chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (CMF)
Number of subjects: 599
Study: 15464665

Group type: EXPERIMENTAL
Intervention: Reteplase
Number of subjects: 1764

Group type: EXPERIMENTAL
Intervention: Combination of reteplase plus abciximab
Number of subjects: 1764

Group type: EXPERIMENTAL
Intervention: Complete ST-segment resolution (>70%)
Number of subjects: 1764

Group type: EXPERIMENTAL
Intervention: Partial ST-segment resolution (<70% to 30%)
Number of subjects: 1764

Group type: EXPERIMENTAL
Intervention: No ST-segment resolution (<30%)
Number of subjects: 1764

Group type: EXPERIMENTAL
Intervention: Worsening ST-segment elevation
Number of subjects: 1764

Group type: EXPERIMENTAL
Intervention: Incomplete ST-segment resolution (<70%)
Number of subjects: 1764
Study: 12240674

Group type: EXPERIMENTAL
Intervention: Rapid sleep loss (0-hr TIB for 1 night)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Slow sleep loss (6-hr TIB for 4 nights)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intermediate sleep loss (4-hr TIB for 2 nights)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No sleep loss (8-hr TIB for 4 nights)
Number of subjects: 12
Study: 9735752

Group type: EXPERIMENTAL
Intervention: Four-layer compression bandaging provided by district nurses
Number of subjects: 0
Study: 7980882

Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.5% in alcohol 70%
Number of subjects: 890

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 890
Study: 2638183

Group type: EXPERIMENTAL
Intervention: Test dentifrice containing 0.3% triclosan, 2% copolymer, and 0.76% sodium monofluorophosphate
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 3
Study: 49746

Group type: EXPERIMENTAL
Intervention: 95% ethanol solution containing 0‐5% chlorhexidine digluconate applied with a gloved hand for two minutes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional gauze applicator for operation sites
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aqueous solution of chlorhexidine applied with a gloved hand
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 70% alcoholic solution of chlorhexidine applied with a gloved hand
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcoholic povidone iodine applied with a gloved hand
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0‐5% chlorhexidine in 95% alcohol rubbed on and allowed to dry
Number of subjects: 0
Study: 31958290

Group type: EXPERIMENTAL
Intervention: Ramucirumab plus docetaxel (ram+doc)
Number of subjects: 1253

Group type: COMPARATOR
Intervention: Docetaxel (doc)
Number of subjects: 1253
Study: 31319165

Group type: EXPERIMENTAL
Intervention: Inhospital bump trajectory (19.0%)
Number of subjects: 1897

Group type: EXPERIMENTAL
Intervention: Sustained increase trajectory (17.6%)
Number of subjects: 1897

Group type: EXPERIMENTAL
Intervention: Dip trajectory (14.5%)
Number of subjects: 1897

Group type: EXPERIMENTAL
Intervention: No significant changes trajectory
Number of subjects: 1897

Group type: EXPERIMENTAL
Intervention: Sustained increase without significant differences
Number of subjects: 1897

Group type: EXPERIMENTAL
Intervention: Overall trajectories
Number of subjects: 1897
Study: 28478975

Group type: EXPERIMENTAL
Intervention: Adalimumab 0.8 mg/kg
Number of subjects: 114

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Adalimumab 0.4 mg/kg
Number of subjects: 114
Study: 26021185

Group type: EXPERIMENTAL
Intervention: Provider communication skills training based on motivational interviewing principles
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (providers who did not receive training)
Number of subjects: 26
Study: 23439345

Group type: EXPERIMENTAL
Intervention: Sports drinks (SPDs)
Number of subjects: 8
Study: 21632652

Group type: EXPERIMENTAL
Intervention: Virtual reality training (60 trials of reaching for fast-moving virtual balls with the dominant hand)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (60 practice trials turning pegs with their non-dominant hand)
Number of subjects: 33
Study: 18050378

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control treatments
Number of subjects: 0
Study: 16760864

Group type: EXPERIMENTAL
Intervention: Balloon-expandable, radially reinforced ePTFE endograft uplining after remote endarterectomy
Number of subjects: 92
Study: 14672962

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) ingestion (10 ml x kg(‐1) x h(‐1) CHO (6%))
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (Pla) ingestion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Muscle glycogen content
Number of subjects: 30

Group type: COMPARATOR
Intervention: Muscle cytokine mRNA (IL‐1beta, IL‐6, IL‐8, TNF‐alpha)
Number of subjects: 30
Study: 11712339

Group type: EXPERIMENTAL
Intervention: Midline approach for combined spinal-epidural anesthesia (CSEA)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Paramedian approach for combined spinal-epidural anesthesia (CSEA)
Number of subjects: 70
Study: 9273036

Group type: EXPERIMENTAL
Intervention: 1 mg/kg lidocaine applied topically to the muscle after opening the conjunctiva
Number of subjects: 140

Group type: COMPARATOR
Intervention: Saline (0.9%)
Number of subjects: 140
Study: 7962904

Group type: EXPERIMENTAL
Intervention: Dual-cured resin composite
Number of subjects: 12

Group type: COMPARATOR
Intervention: Glass polyalkenoate (ionomer) cement
Number of subjects: 12
Study: 3591272

Group type: EXPERIMENTAL
Intervention: Midazolam (0.15 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diazepam (0.2 mg/kg)
Number of subjects: 60
Study: 29889137

Group type: EXPERIMENTAL
Intervention: Mebo ointment
Number of subjects: 161

Group type: COMPARATOR
Intervention: Biafine cream
Number of subjects: 161
Study: 29141665

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) treatment for 6 months
Number of subjects: 151

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients with moderate and severe RA
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients with stable RA
Number of subjects: 151
Study: 26411014

Group type: EXPERIMENTAL
Intervention: Cranberry extract 1 (36 mg of PACs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cranberry extract 2 (36 mg of PACs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cranberry extract 3 (36 mg of PACs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24184894

Group type: EXPERIMENTAL
Intervention: REG1 (25%, 50%, 75%, 100% reversal)
Number of subjects: 640

Group type: COMPARATOR
Intervention: UFH
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: REG1
Number of subjects: 640
Study: 21381962

Group type: EXPERIMENTAL
Intervention: Primary massage of twining manipulation with one finger (PMTMOF)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Conventional tuina manipulation (control)
Number of subjects: 500
Study: 18513171

Group type: EXPERIMENTAL
Intervention: Multimodal, centrally coordinated, multisite hand hygiene culture-change program (HHCCP) implemented over 24 months.
Number of subjects: 2379

Group type: EXPERIMENTAL
Intervention: Statewide roll-out of the same HHCCP over 12 months.
Number of subjects: 2379
Study: 16306456

Group type: EXPERIMENTAL
Intervention: Certoparin (3000 U anti-Xa OD)
Number of subjects: 545

Group type: COMPARATOR
Intervention: UFH (5000 U TID)
Number of subjects: 545
Study: 12841798

Group type: EXPERIMENTAL
Intervention: Emulsion (75 mg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Emulsion (150 mg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Emulsion (300 mg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Emulsion (all doses)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 10822931

Group type: EXPERIMENTAL
Intervention: Sickle Cell Disease (SCD) males over the age of 10 years
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sickle Cell Disease (SCD) males aged 10-18 years
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sickle Cell Disease (SCD) females over the age of 10 years
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sickle Cell Disease (SCD) subjects under the age of 10 years
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sickle Cell Disease (SCD) females
Number of subjects: 48
Study: 8850404

Group type: EXPERIMENTAL
Intervention: Gabexate mesilate (GM) 2 mg/kg/h in a central venous catheter
Number of subjects: 30

Group type: COMPARATOR
Intervention: No GM (control group)
Number of subjects: 30
Study: 1626799

Group type: EXPERIMENTAL
Intervention: Allergen solution
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control solution
Number of subjects: 16
Study: 6203289

Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg X 3 daily for four weeks
Number of subjects: 27
Study: 31329184

Group type: EXPERIMENTAL
Intervention: Comprehensive anti-edematous therapy (CAET)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Basic therapy with a conventional lymphovenous tonic and elastic compression (Control)
Number of subjects: 60
Study: 28786423

Group type: EXPERIMENTAL
Intervention: Lapatinib treatment
Number of subjects: 4482

Group type: EXPERIMENTAL
Intervention: Lapatinib and taxane combination
Number of subjects: 4482
Study: 26763145

Group type: EXPERIMENTAL
Intervention: medetomidine (10 μg/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: medetomidine with MK-467 (250 μg/kg)
Number of subjects: 8
Study: 24458508

Group type: EXPERIMENTAL
Intervention: RTS (Resistance Training plus supplementation)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: RT (Resistance Training only)
Number of subjects: 22

Group type: COMPARATOR
Intervention: C (Control group)
Number of subjects: 22
Study: 22382727

Group type: EXPERIMENTAL
Intervention: Educational booklet 'Your Back Operation'
Number of subjects: 117
Study: 20458123

Group type: EXPERIMENTAL
Intervention: Acupuncture while under anaesthesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 20
Study: 17384453

Group type: EXPERIMENTAL
Intervention: Candesartan for 6 months
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 48
Study: 16269882

Group type: EXPERIMENTAL
Intervention: Neostigmine 1.5 mg and Atropine 0.5 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Spontaneous resolution (Control group)
Number of subjects: 40
Study: 12393766

Group type: EXPERIMENTAL
Intervention: Ropivacaine 5 mg ml(-1), 3.5 ml (17.5 mg)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Bupivacaine 5 mg ml(-1), 3.5 ml (17.5 mg)
Number of subjects: 66
Study: 9926189

Group type: EXPERIMENTAL
Intervention: Buprenorphine 100 micrograms i.a. (group A)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% 50 mg i.a. (group B)
Number of subjects: 48

Group type: COMPARATOR
Intervention: NaCl 0.9% i.a. and buprenorphine 100 micrograms i.m. (group C)
Number of subjects: 48

Group type: COMPARATOR
Intervention: NaCl 0.9% i.a. and NaCl 0.9% i.m. (group D)
Number of subjects: 48
Study: 7482412

Group type: EXPERIMENTAL
Intervention: 1-desamino-8-D-arginine vasopressin (DDAVP) infusion
Number of subjects: 62
Study: 2179398

Group type: EXPERIMENTAL
Intervention: Cyclofenil
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study: 528086

Group type: EXPERIMENTAL
Intervention: Preoperative normovolaemic haemodilution with dextran 70
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group receiving 500 ml dextran 70 during operation and again on the second postoperative day
Number of subjects: 57
Study: 30415629

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol) at a dose of 2000 IU per day
Number of subjects: 25871

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25871
Study: 29995008

Group type: EXPERIMENTAL
Intervention: Minimally Invasive Ponto Surgery (MIPS)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Linear incision technique with soft-tissue preservation (control)
Number of subjects: 64
Study: 27769851

Group type: EXPERIMENTAL
Intervention: Active CPAP
Number of subjects: 4

Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 4
Study: 25082741

Group type: EXPERIMENTAL
Intervention: NT‐proCNP levels
Number of subjects: 567
Study: 21833551

Group type: EXPERIMENTAL
Intervention: L: -carnitine supplementation and protein-restricted diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 0
Study: 19444973

Group type: EXPERIMENTAL
Intervention: Winter swimming in ice-cold water (WS) for 20 seconds, three times a week for 12 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Whole body cryotherapy (WBC) for 2 minutes, three times a week for 12 weeks
Number of subjects: 12
Study: 17606725

Group type: EXPERIMENTAL
Intervention: Erlotinib (single agent)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Erlotinib plus gemcitabine
Number of subjects: 444
Study: 14674933

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 12189358

Group type: EXPERIMENTAL
Intervention: Controlled-release flecainide acetate (100 mg/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Controlled-release flecainide acetate (200 mg/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Controlled-release flecainide acetate
Number of subjects: 24

Group type: COMPARATOR
Intervention: Immediate-release flecainide acetate
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 24
Study: 10426254

Group type: EXPERIMENTAL
Intervention: Conventional and colour Doppler sonography
Number of subjects: 1074

Group type: EXPERIMENTAL
Intervention: Transvaginal sonography
Number of subjects: 1074

Group type: EXPERIMENTAL
Intervention: Doppler sonography
Number of subjects: 1074
Study: 7768664

Group type: EXPERIMENTAL
Intervention: Full polyethylene patellar component
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Metal backed component
Number of subjects: 203

Group type: COMPARATOR
Intervention: Patellar debridement without resurfacing
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 203
Study: 1693497

Group type: EXPERIMENTAL
Intervention: Krypton red laser photocoagulation
Number of subjects: 247
Study: 678389

Group type: EXPERIMENTAL
Intervention: 6 mg piretanide/day
Number of subjects: 9

Group type: COMPARATOR
Intervention: 40 mg frusemide/day
Number of subjects: 9

Group type: COMPARATOR
Intervention: 1 mg bumetanide/day
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: All three diuretics
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Piretanide
Number of subjects: 9
Study: 31266149

Group type: EXPERIMENTAL
Intervention: Ponesimod (10 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ponesimod (10 mg) with cenerimod (2 mg once daily) at near half steady-state (Day 18)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ponesimod (10 mg) with cenerimod (2 mg once daily) at steady-state (Day 37)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cenerimod (2 mg once daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 27728839

Group type: EXPERIMENTAL
Intervention: Progressive resistance plus balance training (PRBT) - six months of twice weekly machine-based, moderate to high intensity, supervised training followed by six months of unsupervised follow-up.
Number of subjects: 248

Group type: COMPARATOR
Intervention: Usual activities (Control) - six months of usual activities before entering the PRBT and follow-up phases.
Number of subjects: 248
Study: 26375464

Group type: EXPERIMENTAL
Intervention: ALVAC-HIV
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Remune
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 22580932

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (600,000 IU monthly for 8 weeks)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 20535607

Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg
Number of subjects: 487

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487
Study: 19750476

Group type: EXPERIMENTAL
Intervention: 10 ml of 0.5% bupivacaine with 1:200,000 epinephrine
Number of subjects: 26

Group type: COMPARATOR
Intervention: 10 ml of normal saline solution (placebo)
Number of subjects: 26
Study: 15872336

Group type: EXPERIMENTAL
Intervention: Peroral estrogen (PE) therapy
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen therapy
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Estrogen therapy (combined)
Number of subjects: 64
Study: 10576182

Group type: EXPERIMENTAL
Intervention: Topical vaginal 5-fluorouracil (5-FU) cream (2 g) for 6 months
Number of subjects: 101

Group type: COMPARATOR
Intervention: Observation after standard treatment for 6 months
Number of subjects: 101
Study: 8724022

Group type: EXPERIMENTAL
Intervention: Claversal (1g tid)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 1757610

Group type: EXPERIMENTAL
Intervention: 0.05% halobetasol propionate cream
Number of subjects: 264

Group type: COMPARATOR
Intervention: 0.05% betamethasone dipropionate cream
Number of subjects: 264

Group type: COMPARATOR
Intervention: 0.05% clobetasol 17-propionate cream
Number of subjects: 264
Study: 6925983

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) + BCG
Number of subjects: 217

Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU)
Number of subjects: 217

Group type: COMPARATOR
Intervention: No further treatment (surgery only)
Number of subjects: 217
Study: 31901799

Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0
Study: 30702322

Group type: EXPERIMENTAL
Intervention: Partners for Change Outcome Monitoring System (PCOMS)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 170
Study: 29931709

Group type: COMPARATOR
Intervention: Methylphenidate (MPH) for 12 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Neurofeedback (NF) with 30 sessions
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Neurofeedback (NF)
Number of subjects: 40
Study: 26849812

Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma (PRP) injection
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo injection (saline)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cohort study (not randomized)
Number of subjects: 9
Study: 24947034

Group type: EXPERIMENTAL
Intervention: Estrogen (Premarin)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 30